SAB Biotherapeutics, Inc. (SABS)
$3.80-$0.14 (-3.56%) Today
Samuel J. Reich - Officer
Rita JainSAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Tax withholding / forfeiture | 1 | 988 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
28 Form 4 filings on record, the earliest from Nov 5, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Alexandra Kropotova - Officer | Tax withholding / forfeiture | Common Stock | 988 | - | - | |
| Alexandra Kropotova - Officer | Tax withholding / forfeiture | Common Stock | 988 | - | - | |
| Eddie Joe Sullivan - Officer | Grant or award | Stock option (right to buy) | 3,000,000 | $0.00 | - | |
| Samuel J. Reich - Officer | Grant or award | Stock option (right to buy) | 4,800,000 | $0.00 | - | |
| Christoph Lawrence Bausch - Officer | Grant or award | Stock option (right to buy) | 1,800,000 | $0.00 | - | |
| Alexandra Kropotova - Officer | Grant or award | Stock option (right to buy) | 2,400,000 | $0.00 | - | |
| Lucy To - Officer | Grant or award | Stock option (right to buy) | 2,400,000 | $0.00 | - | |
| Rita Jain | Grant or award | Stock Option (right to buy) | 240,000 | $0.00 | - | |
 David Zaccardelli | Grant or award | Stock Option (right to buy) | 240,000 | $0.00 | - | |
| Jay S. Skyler | Grant or award | Stock Option (right to buy) | 150,000 | $0.00 | - | |
| William James Polvino | Grant or award | Stock Option (right to buy) | 150,000 | $0.00 | - | |
| Erick Lucera | Grant or award | Stock option (right to buy) | 150,000 | $0.00 | - | |
| Helen K. Ellias | Grant or award | Stock Option (right to buy) | 150,000 | $0.00 | - | |
| Scott Giberson | Grant or award | Stock Option (right to buy) | 150,000 | $0.00 | - | |
| David Link | Grant or award | Stock Option (right to buy) | 150,000 | $0.00 | - | |
| Alexandra Kropotova - Officer | Tax withholding / forfeiture | Common Stock | 988 | - | - | |
| Sessa Capital (Master), L.P. - Director | Option exercise | Common Stock | 1,740,000 | $1.75 | $3.04M | |
| Sessa Capital (Master), L.P. - Director | Option exercise | Series B Convertible Preferred Stock | 17,400 | - | - | |
| Andrew Moin | Option exercise | Common Stock | 1,740,000 | $1.75 | $3.04M | |
| Andrew Moin | Option exercise | Series B Convertible Preferred Stock | 17,400 | - | - | |
| Alexandra Kropotova - Officer | Tax withholding / forfeiture | Common Stock | 1,977 | - | - | |
| Eddie Joe Sullivan - Officer | Grant or award | Stock Option (right to buy) | 3,000,000 | $0.00 | - | |
| Lucy To - Officer | Grant or award | Stock Option (right to buy) | 1,200,000 | $0.00 | - | |
| Alexandra Kropotova - Officer | Grant or award | Stock Option (right to buy) | 2,400,000 | $0.00 | - | |
| Christoph Lawrence Bausch - Officer | Grant or award | Stock Option (right to buy) | 600,000 | $0.00 | - | |
| Samuel J. Reich - Officer | Grant or award | Stock Option (right to buy) | 4,800,000 | $0.00 | - | |
| Sessa Capital (Master), L.P. - Director | Grant or award | Series B Convertible Preferred Stock | 228,500 | - | - | |
| Sessa Capital (Master), L.P. - Director | Grant or award | Warrants (right to buy) | 228,500 | - | - | |
| Sessa Capital (Master), L.P. - Director | Grant or award | Warrants (right to buy) | 114,250 | - | - | |
| Andrew Moin | Grant or award | Series B Convertible Preferred Stock | 228,500 | - | - | |
| Andrew Moin | Grant or award | Warrants (right to buy) | 228,500 | - | - | |
| Andrew Moin | Grant or award | Warrants (right to buy) | 114,250 | - | - | |
| Alexandra Kropotova - Officer | Tax withholding / forfeiture | Common Stock | 9,072 | - | - | |
| Helen K. Ellias | Grant or award | Stock Option (right to buy) | 20,000 | $0.00 | - | |
| Helen K. Ellias | Grant or award | Stock Option (right to buy) | 35,000 | $0.00 | - |
SAB Biotherapeutics, Inc. (SABS) had 1 insider filing in the last 90 days, with the most recent on 2026-06-26. The full record for SABS runs to 28 Form 4 filings, the earliest from 2024-11-05. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of SABS were filed in the last 90 days.
No insider sales of SABS were filed in the last 90 days.
This page tracks SABS Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add SABS to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
